The Obama Administration through the U.S. Treasury Department will clamp down further on corporate income tax-avoiding inversion deals by U.S. companies with foreign rivals. There is a pending inversion deal between U.S. drug maker Pfizer Inc. and smaller Irish competitor Allergan, Plc. (Reuters)